Acelyrin (SLRN) Competitors $5.68 -0.22 (-3.73%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SLRN vs. AMPH, TWST, ARWR, SRRK, ACAD, CGON, HRMY, VERA, LBPH, and IDYAShould you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Amphastar Pharmaceuticals (AMPH), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), CG Oncology (CGON), Harmony Biosciences (HRMY), Vera Therapeutics (VERA), Longboard Pharmaceuticals (LBPH), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Acelyrin vs. Amphastar Pharmaceuticals Twist Bioscience Arrowhead Pharmaceuticals Scholar Rock ACADIA Pharmaceuticals CG Oncology Harmony Biosciences Vera Therapeutics Longboard Pharmaceuticals IDEAYA Biosciences Amphastar Pharmaceuticals (NASDAQ:AMPH) and Acelyrin (NASDAQ:SLRN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Does the MarketBeat Community favor AMPH or SLRN? Amphastar Pharmaceuticals received 377 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 66.44% of users gave Amphastar Pharmaceuticals an outperform vote while only 62.50% of users gave Acelyrin an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39266.44% Underperform Votes19833.56% AcelyrinOutperform Votes1562.50% Underperform Votes937.50% Which has more risk & volatility, AMPH or SLRN? Amphastar Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Acelyrin has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Do analysts rate AMPH or SLRN? Amphastar Pharmaceuticals presently has a consensus target price of $63.00, suggesting a potential upside of 24.38%. Acelyrin has a consensus target price of $11.17, suggesting a potential upside of 101.56%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Acelyrin 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to AMPH or SLRN? In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Acelyrin. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 5 mentions for Acelyrin. Acelyrin's average media sentiment score of 1.23 beat Amphastar Pharmaceuticals' score of 1.22 indicating that Acelyrin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acelyrin 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, AMPH or SLRN? Amphastar Pharmaceuticals has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$712.89M3.51$137.54M$2.8917.69AcelyrinN/AN/A-$381.64M-$2.38-2.29 Do institutionals & insiders have more ownership in AMPH or SLRN? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 13.6% of Acelyrin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is AMPH or SLRN more profitable? Amphastar Pharmaceuticals has a net margin of 23.36% compared to Acelyrin's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 29.79% beat Acelyrin's return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals23.36% 29.79% 12.75% Acelyrin N/A -46.10%-41.46% SummaryAmphastar Pharmaceuticals beats Acelyrin on 11 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.>> Dive into the Workshop Here Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRN vs. The Competition Export to ExcelMetricAcelyrinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$540.69M$7.12B$5.36B$8.41BDividend YieldN/A8.77%5.21%4.20%P/E Ratio-1.9216.49140.7917.72Price / SalesN/A253.781,450.4377.41Price / CashN/A50.1638.8833.56Price / Book0.815.664.724.58Net Income-$381.64M$151.16M$115.38M$225.57M7 Day Performance-8.54%-1.53%-0.69%-0.35%1 Month Performance10.75%6.18%3.71%1.73%1 Year Performance-46.39%40.15%38.84%32.96% Acelyrin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRNAcelyrin3.3979 of 5 stars$5.68-3.7%$11.17+96.6%-42.2%$562.47MN/A-2.00135Upcoming EarningsPositive NewsGap DownAMPHAmphastar Pharmaceuticals4.6368 of 5 stars$51.15-0.5%$63.00+23.2%+12.4%$2.50B$712.89M16.341,761Upcoming EarningsPositive NewsTWSTTwist Bioscience4.1818 of 5 stars$42.65+0.3%$51.22+20.1%+186.3%$2.48B$295.21M-11.16990ARWRArrowhead Pharmaceuticals4.1933 of 5 stars$19.98-1.0%$45.33+126.9%-15.1%$2.48B$19.65M-4.28400SRRKScholar Rock4.7445 of 5 stars$30.93+1.6%$33.29+7.6%+160.1%$2.47B$33.19M-13.93140Upcoming EarningsPositive NewsACADACADIA Pharmaceuticals4.7826 of 5 stars$14.74flat$25.56+73.4%-33.6%$2.44B$890.53M81.89510Upcoming EarningsCGONCG Oncology3.1468 of 5 stars$36.19-2.9%$63.88+76.5%N/A$2.41B$650,000.000.0061Short Interest ↓HRMYHarmony Biosciences4.8984 of 5 stars$41.49+16.1%$44.38+7.0%+71.5%$2.36B$656.11M21.28200Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeVERAVera Therapeutics3.3266 of 5 stars$42.97-9.2%$53.56+24.6%+275.9%$2.36BN/A-19.4440Analyst ForecastInsider SellingLBPHLongboard Pharmaceuticals1.6389 of 5 stars$59.57-0.2%$59.560.0%+1,005.6%$2.32BN/A-27.7120Upcoming EarningsPositive NewsIDYAIDEAYA Biosciences4.3471 of 5 stars$29.86-0.5%$55.45+85.7%+14.4%$2.26B$11.96M-13.6380Upcoming EarningsAnalyst ForecastShort Interest ↓ Related Companies and Tools Related Companies AMPH Alternatives TWST Alternatives ARWR Alternatives SRRK Alternatives ACAD Alternatives CGON Alternatives HRMY Alternatives VERA Alternatives LBPH Alternatives IDYA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLRN) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
